All Stories

Acelyrin to be absorbed into Alumis in all-stock merger

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

Feb 9, 2025 - 21:44
 0
Acelyrin to be absorbed into Alumis in all-stock merger
Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.
Read More

Tags:

Previous Article

Bristol Myers backs out of Dupixent fight, axing allergy asset despite phase 3 win

Next Article

Chutes & Ladders—J&J vet jumps to Affinia

Related Posts

Cullinan CEO talks autoimmune pivot, upcoming lupus readout and his 'thriller or killer' approach

Cullinan CEO talks autoimmune pivot, upcoming lupus rea...

Feb 9, 2025  0

Septerna drops lead asset over bilirubin side effects 4 months after going public

Septerna drops lead asset over bilirubin side effects 4...

Feb 18, 2025  0

Third Harmonic halves headcount to take urticaria drug into phase 2 despite side effects

Third Harmonic halves headcount to take urticaria drug ...

Feb 11, 2025  0